DRHC

Dryden Regional Health Centre

58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6
TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

APPENDIX C - ATTESTATION

Prepared in accordance with section 15 of the *Broader Public Sector Accountability*Act, 2010 (BPSAA)

TO: The Board of Directors of Dryden Regional Health Centre, (the "Board")

FROM: Doreen Armstrong-Ross

President & CEO

Dryden Regional Health Centre

Date: June 23, 2025

RE: April 1, 2024 to March 31, 2025 ("the Applicable Period")

On behalf of the Dryden Regional Health Centre (the Hospital) I attest to:

- the completion and accuracy of reports required of the Hospital pursuant to section
 6 of the BPSAA on the use of consultants;
- the Hospital's compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;
- the Hospital's compliance with any applicable expense claims directives issued under section 10 of the BPSAA by the Management Board of Cabinet;
- the Hospital's compliance with any applicable perquisite directives issued under section 11.1 of the BPSAA by the Management Board of Cabinet; and
- the Hospital's compliance with any applicable procurement directives issued under section 12 of the BPSAA by the Management Board of Cabinet,

during the Applicable Period.

In making this attestation, I have exercised care and diligence that would reasonably be expected of a President & CEO in these circumstances, including making due inquiries of Hospital staff that have knowledge of these matters.





58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6
TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

I further certify that any material exceptions to this attestation are documented in the attached Schedule A.

Dated at Dryden, Ontario this June 23, 2025.

Doreen Armstrong-Ross

President & CEO

Dryden Regional Health Centre

I certify that this attestation has been approved by the board of the Dryden Regional Health Centre on June 23, 2025.

Vanessa Simpson Chair of the Board

Dryden Regional Health Centre

DRHC

Dryden Regional Health Centre

58 GOODALL STREET, P.O. BOX 3003, DRYDEN, ONTARIO P8N 2Z6
TELEPHONE (807)223-8200 FAX (807)223-8628

Respect • Integrity • Humility • Compassion • Accountability

SCHEDULE A to Attestation

Material Exception to Declare

1. Exceptions to the completion and accuracy of reports required in section 6 of the BPSAA on the use of consultants;

No Known Exceptions.

2. Exceptions to the Hospital's compliance with the prohibition in section 4 of the BPSAA on engaging lobbyist services using public funds;

No Known Exceptions.

3. Exceptions to the Hospital's compliance with the expense claims directive issued under section 10 of the BPSAA by the Management Board of Cabinet;

No Known Exceptions.

4. Exceptions to the Hospital's compliance with the perquisites directive issued under section 11.1 of the BPSAA by the Management Board of Cabinet; and

No Known Exceptions.

5. Exceptions to the Hospital's compliance with the procurement directive issued under section 12 of the BPSAA by the Management Board of Cabinet.

No Known Exceptions.

6. Exceptions to the Hospital's compliance with the business plans directive issued under section 13 of the BPSAA by the Management Board of Cabinet.

No Known Exceptions.

Vanessa Simpson Chair of the Board Dryden Regional Health Centre



March 25, 2025

Attestation to the BPSAA Supply Chain Secretariat BPS Directive and Canada Free Trade Agreement (CFTA) Compliance

Dear Member,

Mohawk Medbuy Corporation fully understands and abides by the Ontario Ministry of Finance Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA) meant to ensure that publicly funded goods and services are acquired by BPS organizations through a process that is open, fair, and transparent.

On behalf of Mohawk Medbuy Corporation, we attest that all contracting services performed on the Members' behalf for the applicable period of April 1, 2024 – March 31, 2025, are in compliance with the Broader Public Sector Supply Chain Directives and the Canada Free Trade Agreement (CFTA). Exceptions, for contracts on which the Member participated occurring during the twelve (12) month reporting period are noted on the attached document with supporting explanations.

In making this attestation, we have exercised care and diligence that would reasonably be expected in these circumstances, including making due inquires and reviewing results of the self-assessment audits we have completed.

I, Marc Lemaire, Senior Vice President, Strategic Sourcing, I, Dale Thomson, Senior Vice President, National Programs & Sourcing Operations, I, Raechel Griffin, Vice President, Capital, FFE, and Nutrition Services Procurement I, Ally Dhalla, Senior Vice President Pharmacy and Clinical Services & Innovation have the signing authority to make this commitment on behalf of Mohawk Medbuy Corporation.

MOHAWK MEDBUY CORPORATION

Marc Lemaire Senior Vice President, Strategic

Sourcina

mlemaire@mohawkmedbuy.ca

Dale Thomson
Senior Vice President, National
Programs & Sourcing

Dale Thoms

Operations

dthomson@mohawkmedbuy.ca

Raechel Griffin

Vice President, Capital, FFE and Nutrition Services

Draguramant

Procurement

rgriffin@mohawkmedbuy.ca

Ally Dhalla

Senior Vice President, Pharmacy and Clinical Services & Innovation adhalla@mohawkmedbuy.ca

* Reported Spend indicates Member provided data for the Attestation Period. Note that contracts may have started or ended at various points within the Attestation period. Data compiled from October 2023 to September 2024

P - ND indicates Member participation on contract, however spend data not provided/available

NP - Not Participating

DRYDEN REGIONAL

HEALTH CENTRE New Contract Expiry **Current Contract** Contract No. **Contract Name Supplier Name Contract Start Date** Date (for extended **Exception Type** Justification Code SC10046 **Expiry Date** MMCL C10012 MMCL BLOOD TUBES 2017 - GBO - PA GREINER BIO ONE April 1, 2017 March 31, 2024 December 31, 2025 Appendix A - Limited Tender C(i) C(ii) P-ND OR BASIC SURGICAL INSTRUMENTS 2017 - INTEGRA OR C10047 INTEGRA CANADA ULC December 1, 2017 November 30, 2024 January 31, 2025 Appendix A - Limited Tender D P-ND C10181 OR LASER FIBERS 2017 - CLARION MEDICAL - PA CLARION MEDICAL TECHNOLO November 1, 2017 July 31, 2024 D P-ND January 31, 2026 Appendix A - Limited Tender OR SKIN PREP SYSTEMS 2018 - 3M CANADA C10220 3M HEALTHCARE CANADA COI June 1, 2018 May 31, 2024 July 31, 2024 Appendix A - Limited Tender D P-ND lor C10221 OR SKIN PREP SYSTEMS 2018 - BECTON DICKINSON BECTON DICKINSON CANADA June 1, 2018 May 31, 2024 July 31, 2024 Appendix A - Limited Tender P-ND OR SKIN PREP SYSTEMS 2018 - CARDINAL HEALTH CARDINAL HEALTH CANADA IN June 1, 2018 May 31, 2024 July 31, 2024 D Appendix A - Limited Tender lor P-ND OR SKIN PREP SYSTEMS 2018 - MEDLINE CANADA MEDLINE CANADA INC June 1, 2018 May 31, 2024 D July 31, 2024 OR Appendix A - Limited Tender P-ND OR C10224 OR SKIN PREP SYSTEMS 2018 - MEDLINE MEDLINE CANADA INC June 1, 2018 May 31, 2024 July 31, 2024 Appendix A - Limited Tender D P-ND C10225 OR SKIN PREP SYSTEMS 2018 - OMEGA LABORATORIES OMEGA LABORATORIES LTD. June 1, 2018 May 31, 2024 July 31, 2024 Appendix A - Limited Tender D P-ND C10257 MMCL CORE UROLOGY PRODUCTS 2018 - MEDLINE MEDLINE CANADA INC MMCL October 1, 2018 September 30, 2024 December 31, 2024 Appendix A - Limited Tender P-ND C10258 MMCL CORE UROLOGY PRODUCTS 2018 - BARD December 31, 2024 Appendix A - Limited Tender MMCL BARD CANADA INC October 1, 2018 September 30, 2024 D P-ND C10260 OR HERNIA REPAIR PRODUCTS 2018 - BARD BARD CANADA INC November 1, 2018 October 31, 2024 January 31, 2025 D OR Appendix A - Limited Tender P-ND MEDTRONIC CANADA -ULC. D OR C10262 OR HERNIA REPAIR PRODUCTS 2018 - MEDTRONIC November 1, 2018 October 31, 2024 January 31, 2025 Appendix A - Limited Tender P-ND OR C10263 OR HERNIA REPAIR PRODUCTS 2018 - JUMP JOHNSON & JOHNSON MEDTE November 1, 2018 October 31 2024 January 31, 2025 D P-ND Appendix A - Limited Tender MMNCI C10283 MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 CANADIAN HOSPITAL SPECIAL May 10, 2018 December 31, 2024 September 30, 2025 Appendix A - Limited Tender D P-ND MMCL C10287 MMCL TRAYS 2018 - CARDINAL CARDINAL HEALTH CANADA IN October 1, 2018 September 30, 2024 December 31, 2024 Appendix A - Limited Tender D P-ND August 1, 2028 C10290 INNOV GEKO 2018 PA - TRUDELL MEDICAL MARKETING LTD TRUDELL MEDICAL MARKETIN July 31, 2024 July 31, 2026 Appendix A - Limited Tender B(iii) INNOV P-ND C10381 OR BIOLOGIC MESH 2018 - ABBVIE ABBVIE CORPORATION November 1, 2018 October 31, 2024 January 31, 2025 P-ND lor Appendix A - Limited Tender OR BIOLOGIC MESH 2018 - MEDTRONIC CANADA MEDTRONIC CANADA -ULC. Appendix A - Limited Tender OR C10387 November 1, 2018 October 31, 2024 January 31, 2025 D P-ND MMNCL C10452 MMNCL DRY CELL BATTERIES 2019 - CARDINAL CARDINAL HEALTH April 1, 2019 March 31, 2024 November 30, 2024 Appendix A - Limited Tender D P-ND C10500 MMNCL CHEMICALS - DIETARY & LAUNDRY 2019 - BUNZL BUNZL CANADA INC September 1, 2019 August 30, 2026 Appendix A - Limited Tender MMNCI August 31, 2024 P-ND C10654 MMCL BREAST PUMPS & ACCESSORIES 2019 - MEDELA MEDELA CANADA INC November 1, 2019 July 31, 2025 P-ND MMCL January 31, 2025 Appendix A - Limited Tender C10865 BAUSCH HEALTH, CANADA IN June 9, 2023 January 31, 2024 lрн PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS BHC 2020 Appendix A - Limited Tender P-ND C10958 PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NEG GSK 2021 В **IPH** GLAXOSMITHKLINE June 1, 2023 January 31, 2024 Appendix A - Limited Tender P-ND November 30, 2024 Appendix A - Limited Tender D OR OR SPONGES 2021 - MEDI INF - PA MEDI INF March 1 2021 May 31 2024 P-ND November 30, 2024 Appendix A - Limited Tender D C11038 OR SPONGES 2021 - MEDQUEST - PA MEDQUEST (WAS STEVENS) March 1, 2021 May 31, 2024 P-ND MILR C11140 MILR TEST URINALYSIS 2021 - SIEMENS - PA SIEMENS HEALTHCARE LIMITI July 1, 2021 June 30, 2024 August 31, 2024 Appendix A - Limited Tender D P-ND PH C11175 PH INJECTABLE PHARMACEUTICALS NEG BAX 2021 BAXTER CORPORATION October 1, 2024 May 31, 2028 A(i) P-ND Appendix A - Limited Tender PH C11216 PH INJECTABLE PHARMACEUTICALS AURO 2021 AURO PHARMA INC June 19, 2023 September 30, 2024 P-ND Appendix A - Limited Tender В FRESENIUS KABI CANADA LTD lрн C11223 PH INJECTABLE PHARMACEUTICALS FRK 2021 March 17, 2024 September 30, 2024 Appendix A - Limited Tender В P-ND Appendix A - Limited Tender PH C11230 PH INJECTABLE PHARMACEUTICALS MTP 2021 METHAPHARM August 25, 2023 September 30, 2024 B P-ND PH C11234 PH INJECTABLE PHARMACEUTICALS OME 2021 OMEGA LABORATORIES LTD. August 21, 2023 September 30, 2024 Appendix A - Limited Tender В P-ND РΗ C11307 PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2021 JAMP PHARMA CORPORATION May 5, 2023 September 30, 2024 Appendix A - Limited Tender P-ND PH BAXTER CORPORATION October 1, 2024 May 31, 2028 Appendix A - Limited Tender A(i) C11336 PH INJECTABLE MICRONUTRIENTS BAX 2021 P-ND April 28, 2023 P-ND PH C11427 PH INJECTABLE PHARMACEUTICALS AGT 2022 LABORATOIRE AGUETTANT C September 30, 2024 Appendix A - Limited Tender January 1, 2025 Appendix A - Limited Tender B(ii) PН C11547 PH ONCOLOGY MEDU 2022 MEDUNIK CANADA September 30, 2025 P-ND July 14, 2023 Appendix A - Limited Tender PH C11557 PH PARENTERAL NUTRITION SOLUTIONS + LIPIDS FRK 2022 FRESENIUS KABI CANADA LTI October 31, 2025 R P-ND PH C11579 PH ONCOLOGY APX 2022 APOTEX INC January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND PH C11580 PH ONCOLOGY ASP 2022 ASPEN PHARMACARE CANAD January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND B(ii) lрн C11582 PH ONCOLOGY BAX 2022 BAXTER CORPORATION January 1, 2025 September 30, 2025 Appendix A - Limited Tender P-ND lрн C11585 PH ONCOLOGY SPI 2022 SEARCHLIGHT PHARMA INC. January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND Appendix A - Limited Tender PH C11586 PH ONCOLOGY FRK 2022 FRESENIUS KABI CANADA LTI January 1, 2025 September 30, 2025 B(ii) P-ND PH C11587 PH ONCOLOGY GMP 2022 GENERIC MEDICAL PARTNERS January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND PH C11588 PH ONCOLOGY MAR 2022 MARCAN PHARMACEUTICALS January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND PH C11590 PH ONCOLOGY NAT 2022 NATCO PHARMA (CANADA) INC January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND PH C11596 PH ONCOLOGY SAV 2022 SANOFI-AVENTIS CANADA INC January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND lрн C11597 PH ONCOLOGY TAR 2022 TARO PHARMACEUTICALS IN January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND Appendix A - Limited Tender PH VALEO PHARMA January 1, 2025 September 30, 2025 B(ii) P-ND C11599 PH ONCOLOGY VLO 2022 PH C11623 PH RESERVE ONCOLOGY APX 2022 APOTEX INC January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND PH C11634 PH RESERVE ONCOLOGY STM 2022 STERIMAX January 1, 2025 September 30, 2025 Appendix A - Limited Tender B(ii) P-ND B(ii) РН January 1, 2025 C11643 PH RESERVE ONCOLOGY PEI 2022 PEIZER CANADA ULO September 30, 2025 Appendix A - Limited Tender P-ND B(ii) PH C11648 PH RESERVE ONCOLOGY JAMP 2022 JAMP PHARMA CORPORATION January 1, 2025 September 30, 2025 Appendix A - Limited Tender P-ND PН C11715 PH PHARMACY SUPPLIES PHS 2022 PHARMASYSTEMS INC November 1, 2023 November 30, 2025 Appendix A - Limited Tender В P-ND PH C11861 PH PREFILLED LOCK FLUSH SYRINGES + DEVICES BD 2023 BECTON DICKINSON CANADA May 1, 2023 April 30, 2026 December 31, 2028 Appendix A - Limited Tender B(ii) P-ND PH C11871 PH ORAL SOLID PHARMACEUTICALS APX 2023 APOTEX INC July 1, 2023 March 31, 2027 Appendix A - Limited Tender В P-ND PH C11899 PH ORAL SOLID PHARMACEUTICALS TEVA 2023 TEVA CANADA LIMITED INC July 1, 2023 March 31, 2027 Appendix A - Limited Tender P-ND PH C12122 PH BIOSIMILAR ONCOLOGY NCCNEG ORG 2023 ORGANON CANADA INC July 1, 2023 September 30, 2024 Appendix A - Limited Tender P-ND lрн C12158 PH ONCOLOGY EISAI 2023 FISALI IMITED February 1, 2024 September 30, 2025 Appendix A - Limited Tender В P-ND Appendix A - Limited Tender PH C12170 PH INJECTABLE PHARMACEUTICALS IUL 2023 INDIVIOR CANADA LTD. September 26, 2023 September 30, 2024 P-ND PH C12283 PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS BALC 2024 BAUSCH + LOMB CORPORATI February 1, 2024 January 31, 2027 Appendix A - Limited Tender A(ii) & B P-ND PH C12293 PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KEN 2024 KENVUE CANADA INC. February 1, 2024 January 31, 2027 Appendix A - Limited Tender P-ND January 31, 2027 PH PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NOR 2024 NORWELL CONSUMER HEALTI February 1, 2024 Appendix A - Limited Tender A(ii) & B P-ND C12300 February 1, 2024 PH PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NVR 2024 NOVARTIS PHARMACEUTICAL January 31, 2027 Appendix A - Limited Tender A(ii) & B C12301 P-ND PH C12306 PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS PDL 2024 PALADIN PHARMA INC. February 1, 2024 January 31, 2027 Appendix A - Limited Tender A(ii) & B P-ND Appendix A - Limited Tender РН PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS TEVA 2024 February 1, 2024 January 31, 2027 A(ii) & B C12317 TEVA CANADA LIMITED INC P-ND C12318 PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS VLO 2024 VALEO PHARMA February 1, 2024 January 31, 2027 Appendix A - Limited Tender A(ii) & B P-ND

DGDH

PH PH									_
211	C12407	PH RESERVE NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AURO		February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
7	C12408	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS STOM 2024	STOM PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12415	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS HTH 2024	HEALTHMARK SERVICES	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
PH	C12424	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SPI 2024	SEARCHLIGHT PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н		FRI NON INJECTABLE + NON ORAL SOLID FRANMACEUTICALS SFI 2024	SEARCHLIGHT FHARIVATING.				Appendix A - Limited Tender		P-ND
	C12425	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ATL 2024	ATLAS LABORATOIRE INC.	February 1, 2024	January 31, 2027			A(ii) & B	
Η	C12426	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS SFR 2024	SEAFORD PHARMACEUTICALS	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
H	C12436	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS LEO 2024	LEO PHARMA INC	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н	C12442	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS IUL 2024	INDIVIOR CANADA LTD.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н	C12475	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ESS 2023	ESSENTIAL PHARMA	December 15, 2023	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н	C12478	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS COVIS 2024	COVIS PHARMA CANADA LTD.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
H	C12483	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS AAP 2024	AA PHARMA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н	C12520	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS ALC 2024	ALCON CANADA INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
Н	C12523	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS KNI 2024	KNIGHT THERAPEUTICS INC.	February 1, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
H	C12541	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG AMG 2024	AMGEN CANADA INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	В	P-ND
Н	C12542	PH ERYTHROPOIESIS STIMULATING AGENTS NCCNEG JAN 2024	JANSSEN INC.	July 1, 2024	June 30, 2027		Appendix A - Limited Tender	В	P-ND
H	C12690	PH INJECTABLE PHARMACEUTICALS BAY 2024 EXCLUSIVE	BAYER INC.	July 1, 2024	September 30, 2024		Appendix A - Limited Tender	C(ii)	P-ND
			DATER INC.						
Н	C12733	PH NON INJECTABLE + NON ORAL SOLID PHARMACEUTICALS NCCNEG ON HL		February 20, 2024	January 31, 2027		Appendix A - Limited Tender	A(ii) & B	P-ND
IILR	C12749	MILR TEST URINALYSIS 2024 - SIEMENS - PA	SIEMENS HEALTHCARE LIMITE	September 1, 2024	August 8, 2027		Appendix A - Limited Tender	B(v)	P-ND
Н	C12780	PH ONCOLOGY EPI 2024	EUGIA PHARMA INC.	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
Н	C12943	PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS SDZ 2024	SANDOZ CANADA INC	October 1, 2024	May 31, 2027		Appendix A - Limited Tender	A(i)	P-ND
H	C12951	PH INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACARE CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
Н	C12953	PH INJECTABLE PHARMACEUTICALS AVIR 2024	AVIR PHARMA INC.	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
Н				October 1, 2024	May 31, 2028		Appendix A - Limited Tender		P-ND
	C12959	PH INJECTABLE PHARMACEUTICALS HCL 2024	HIKMA CANADA LTD.					A(i)	
Н	C12967	PH INJECTABLE PHARMACEUTICALS MTP 2024	METHAPHARM	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
Н	C12972	PH INJECTABLE PHARMACEUTICALS PFI 2024	PFIZER CANADA ULC	October 1, 2024	May 31, 2028	· · · · · · · · · · · · · · · · · · ·	Appendix A - Limited Tender	A(i)	P-ND
Ή	C12979	PH INJECTABLE PHARMACEUTICALS STM 2024	STERIMAX	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
H	C13032	PH SEVOFLURANE INHALATION ANESTHETIC ABB 2024	ABBVIE CORPORATION	October 1, 2024	September 30, 2026	<u> </u>	Appendix A - Limited Tender	A5 (v)	P-ND
Н	C13033	PH SEVOFLURANE INHALATION ANESTHETIC BAX 2024	BAXTER CORPORATION	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	P-ND
				2 310001 1, 2024	2251011201 00, 2020				1
	C13034		CANADIAN HOSPITAL	October 1, 2024	September 30, 2026		Appendix A - Limited Tender	A5 (v)	L
Ή		PH SEVOFLURANE INHALATION ANESTHETIC CHS 2024	SPECIALTIES LTD.	**			* * *		P-ND
'H	C13054	PH INJECTABLE PHARMACEUTICALS GMP 2024	GENERIC MEDICAL PARTNERS	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
PH H	C13164	PH RESERVE INJECTABLE PHARMACEUTICALS MAR 2024	MARCAN PHARMACEUTICALS I	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
Ή	C13176	PH RESERVE INJECTABLE PHARMACEUTICALS JAMP 2024	JAMP PHARMA CORPORATION	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
H	C13178	PH ONCOLOGY PHARMACEUTICALS AND 2024	ANDONE PHARMACEUTICALS I	January 1, 2025	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND
Ή	C13184	PH RESERVE INJECTABLE PHARMACEUTICALS ASP 2024	ASPEN PHARMACARE CANADA	October 1, 2024	May 31, 2028		Appendix A - Limited Tender	A(i)	P-ND
Ή	C13212	PH RESERVE INJECTABLE PHARMACEUTICALS RDY 2024	DR. REDDY'S LABORATORIES	January 1, 2025	May 31, 2028		Appendix A - Limited Tender	B(ii)	P-ND
	C13324	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE		November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	
Н	C13326	PREPARATIONS BCE 2024 PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE	BCE PHARMA INC. H.E.P.A. FILTER SERVICES	November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	P-ND
	C 13320	PREPARATIONS HFS 2024		November 1, 2024	November 30, 2020		Appendix A - Limited Tender	Article 313 (b) (ii)	P-ND
П			INC.						
'H	C13327	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024	SUPERIOR TESTING SERVICES	November 1, 2024	November 30, 2026		Appendix A - Limited Tender	Article 513 (b) (ii)	P-ND
H H	C13341	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC	October 1, 2024	September 30, 2025		Appendix A - Limited Tender	B(ii)	P-ND P-ND
H H		PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024	SUPERIOR TESTING SERVICES		·			.,,,,	P-ND
H H H	C13341 C13463	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC.	October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender Appendix A - Limited Tender	B(ii) A(i)	P-ND P-ND P-ND
H H H	C13341 C13463 C13464	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS	October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028		Appendix A - Limited Tender Appendix A - Limited Tender Appendix A - Limited Tender	B(ii) A(i) A(i)	P-ND P-ND P-ND P-ND
H H H H	C13341 C13463 C13464 C13542	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD	October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND
H H H H	C13341 C13463 C13464	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS	October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028		Appendix A - Limited Tender Appendix A - Limited Tender Appendix A - Limited Tender	B(ii) A(i) A(i)	P-ND P-ND P-ND P-ND
H H H H H	C13341 C13463 C13464 C13542 C13615	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I	October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND
H H H H H	C13341 C13463 C13464 C13542 C13615 C13689	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUZ 2024 PH INJECTABLE PHARMACEUTICALS SUZ 2024 PH INJECTABLE PHARMACEUTICALS SUZ 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC.	October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS NO 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC.	October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13691	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BGC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS SHO 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS NO 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC.	October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024 October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13691 C13803	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS XEC 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICS INC.	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
	C13341 C13463 C13464 C13642 C13615 C13689 C13690 C13691 C13803 C13804	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS ANO 2024 PH INJECTABLE PHARMACEUTICALS SIM 2024 PH INJECTABLE PHARMACEUTICALS XDD 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC.	October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13690 C13690 C13803 C13804 C13805	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SEQ 2024 PH INJECTABLE PHARMACEUTICALS SEQ 2024 PH INJECTABLE PHARMACEUTICALS SEQ 2024 PH INJECTABLE PHARMACEUTICALS KIL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEI	October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13642 C13615 C13689 C13690 C13691 C13803 C13804	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SIM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS XED 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC.	October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13689 C13689 C13690 C13803 C13803 C13804 C13804 C13805 C13911	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SIM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS XED 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH INJECTABLE PHARMACEUTICALS HI 2024 PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEC LEO PHARMA INC	October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13691 C13803 C13891 C13803 C13891 C13801 C13801 C13805 C13805 C13805 C13911 C14057	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTANMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS KID 2024 PH INJECTABLE PHARMACEUTICALS KID 2024 PH INJECTABLE PHARMACEUTICALS HID 2024 PH INJECTABLE PHARMACEUTICALS HID 2024 PH INJECTABLE PHARMACEUTICALS HID 2024 PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS HER 2024 PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS HER 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEE LEO PHARMA INC FRESENIUS KABI CANADA LTD	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2027		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13801 C13803 C13804 C13805 C13911 C14057	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SIM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS PLE 2024 PH BILOCIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS CONCRETABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS NICONEG FIX 2024 PH BILOCIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS NICONEG FIX 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC FRESENIUS KABI CANADA LTD. LEO PHARMA INC	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2027		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13689 C13690 C13690 C13803 C13804 C13805 C13801 C14057 C14127 C14127	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS HIZ 2024 PH INJECTABLE PHARMACEUTICALS HIZ 2024 PH INJECTABLE PHARMACEUTICALS HIZ 2024 PH BIOLOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS INCOMEG FRK 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMAC CANADA ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITED LEO PHARMA INC FRESENIUS KABI CANADA LTD LEO PHARMA INC	October 1, 2024	September 30, 2025 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13801 C13803 C13804 C13805 C13911 C14057	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SIM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS PLE 2024 PH BILOCIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS CONCRETABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS NICONEG FIX 2024 PH BILOCIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS NICONEG FIX 2024	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC FRESENIUS KABI CANADA LTD. LEO PHARMA INC	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2027	May 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13691 C13803 C13804 C13805 C13911 C141077 C14127 C141202 C68669	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS KID 2024 PH INJECTABLE PHARMACEUTICALS KID 2024 PH INJECTABLE PHARMACEUTICALS HIR 2024 PH INJECTABLE PHARMACEUTICALS HIR 2024 PH INJECTABLE PHARMACEUTICALS IN I SCENEG FREK 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC FESSENIUS KABI CANADA LTD LEO PHARMA INC LEO PHARMA INC LEO PHARMA INC LEADANT BIOSCIENCES, INC. BOSTON SCIENTIFIC	October 1, 2024	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028		Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13801 C13803 C13804 C13805 C13911 C14057 C14127 C14202 C6669 C6672	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS HED 2024 PH INJECTABLE PHARMACEUTICALS POL 2024 PH INJECTABLE PHARMACEUTICALS POL 2024 PH INJECTABLE PHARMACEUTICALS PLR 2024 PH BILOGIC AND BIOSIMILAR INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS BLG 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH RIPPORT PRODUCTS 2015 - JJMP	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMACEUTICALS LEO PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC LEC PHARMA I	October 1, 2024 October 1, 2015 October 1, 2015	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2024 May 31, 2024	May 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C13341 C13463 C13464 C13542 C13645 C13689 C13691 C13603 C13801 C13803 C13804 C13805 C13805 C13807 C14057 C14127 C14127 C14120 C8669 C8672	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BND 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS HIZ 2024 PH INJECTABLE PHARMACEUTICALS HIZ 2024 PH INJECTABLE PHARMACEUTICALS NCONEG FRK 2024 PH INJECTABLE PHARMACEUTICALS LIB 2025 PH INJECTABLE PHARMACEUTICALS LIB 2025 OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KINGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC FRESENIUS KABI CANADA LTD LEO PHARMA INC LEO PHARMA INC LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC JSJ. JSJ. RED LEAF MEDICAL	October 1, 2024 October 1, 2025	September 30, 2025 May 31, 2028 May 31, 2024 May 31, 2024 May 31, 2024 May 31, 2024	May 31, 2025 May 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13801 C13803 C13804 C13805 C13911 C14057 C14127 C14202 C6669 C6672	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS BL 2025 OF PL INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS BL 2025 OF PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR SPONGES 2016 - AMD	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEI LEO PHARMA INC TRESENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL	October 1, 2024 October 1, 2015 October 1, 2015	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2024 May 31, 2024	May 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13645 C13689 C13690 C13691 C13803 C13804 C13805 C13911 C14127 C14127 C14127 C14202 C8669 C8673 C8673	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SWI 2024 PH INJECTABLE PHARMACEUTICALS PL 2024 PH INJECTABLE PHARMACEUTICALS BL 2025 OF PL INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS BL 2025 OF PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR PELVIC SUPPORT PRODUCTS 2015 - JIMP OR SPONGES 2016 - AMD	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEI LEO PHARMA INC TRESENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL	October 1, 2024 October 1, 2015	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13803 C13804 C13805 C13911 C14057 C14127 C14202 C8669 C86672 C8673 C8914 C8915	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BC 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS KED 2024 PH INJECTABLE PHARMACEUTICALS KIN 2024 PH INJECTABLE PHARMACEUTICALS KIN 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS DE 20 20 20 20 20 20 20 20 20 20 20 20 20	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMACANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. LEDITON PHARMACEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICALS INCHEMBANIC PALADIN PHARMA INC. PALADIN PHARMA INC. FRESENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES	October 1, 2024 October 1, 2015 October 1, 2015 October 1, 2015 October 1, 2015 January 1, 2017 January 1, 2017	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH	C13341 C13463 C13464 C13542 C13615 C13689 C13691 C13803 C13891 C13803 C13891 C13805 C13911 C141057 C14127 C14127 C14127 C14202 C8669 C8672 C8814 C8915	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS HIN 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS IN SCONEG FRK 2024 PH INJECTABLE PHARMACEUTICALS IN SCONEG FRK 2024 PH INJECTABLE PHARMACEUTICALS DE 2025 PO PELVIC SUPPORT PRODUCTS 2015 - JBOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JBOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. POFMANN-LA ROCHE LIMITEE LEO PHARMA INC TERSENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J BOSTON SCIENTIFIC J&J AND RED LEAF MEDICAL AMD DERMA SCIENCES DERMA SCIENCES ADVANCED STERILIZATION PR	October 1, 2024 October 1, 2015 January 1, 2017 January 1, 2017	September 30, 2025 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13691 C13803 C13804 C13805 C13911 C14027 C14127 C14127 C14202 C8669 C8672 C8673 C8914 C8915 C8915	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SEP 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS HILE 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JUMP OR PELVIC SUPPORT PRODUCTS 2015 - JUMP OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - AMD MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO HARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC FRESENIUS KABI CANADA LTD. LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC	October 1, 2024 October 1, 2015 October 1, 2016 May 1, 2016 May 1, 2016	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2027 May 31, 2028 May 31, 2024 June 30, 2025	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13691 C13803 C13891 C13803 C13891 C13805 C13911 C141057 C14127 C14127 C14127 C14202 C8669 C8672 C8814 C8915	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS HIN 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS IN SCONEG FRK 2024 PH INJECTABLE PHARMACEUTICALS IN SCONEG FRK 2024 PH INJECTABLE PHARMACEUTICALS DE 2025 PO PELVIC SUPPORT PRODUCTS 2015 - JBOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JBOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. XEDITON PHARMACEUTICALS KNIGHT THERAPEUTICS INC. POFMANN-LA ROCHE LIMITEE LEO PHARMA INC TERSENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J BOSTON SCIENTIFIC J&J AND RED LEAF MEDICAL AMD DERMA SCIENCES DERMA SCIENCES ADVANCED STERILIZATION PR	October 1, 2024 October 1, 2015 January 1, 2017 January 1, 2017	September 30, 2025 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13691 C13803 C13804 C13805 C13801 C14202 C8669 C8672 C86673 C8914 C8915 C8955 C8957	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BC 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS LEO 2025 PH INJECTABLE PHARMACEUTICALS DOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - RED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL IT CONSUMABLES 2016 - STAPLES	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. PALADIN PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEE LEO PHARMA INC FRESENIUS KABI CANADA LTD LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN	October 1, 2024 October 1, 2015 October 1, 2015 October 1, 2015 October 1, 2016 October 1, 2016 October 1, 2016 October 1, 2016 January 1, 2017 January 1, 2017 January 1, 2016 May 1, 2016 May 1, 2016 June 20, 2016	September 30, 2025 May 31, 2028 May 31, 2024 May 31, 2025 June 30, 2025 June 29, 2025	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13645 C13689 C13691 C13803 C13804 C13805 C13911 C14057 C14127 C14127 C14202 C68669 C8672 C8673 C8914 C8915 C8955 C8957 C8964	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SBC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS ALC 2024 PH INJECTABLE PHARMACEUTICALS NC 2024 PH INJECTABLE PHARMACEUTICALS SED 2024 PH INJECTABLE PHARMACEUTICALS HIN 2025 PH INJECTABLE PHARMAC	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO HARMA CANADA INC. HERDANDA PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC. HERSENIUS KABI CANADA LTD. LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J BOSTON SCIENTIFIC J&J BOSTON SCIENTIFIC J&J BOSTON SCIENTIFIC STAPLES PROFESSIONAL CAN STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS	October 1, 2024 October 1, 2025 October 1, 2015 October 1, 2017 January 1, 2017 January 1, 2016 May 1, 2016 June 20, 2016 January 1, 2016	September 30, 2025 May 31, 2028 May 31, 2024 May 31, 2025 June 30, 2025 June 29, 2024 May 31, 2024 May 31, 2024 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
PH P	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13691 C13803 C13804 C13805 C13911 C14027 C14127 C14127 C14202 C8669 C8672 C8673 C8914 C8915 C8915 C8915 C8915 C8915 C8916 C99109 C9111	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BWC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SED 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS BUD 2025 PH INJECTABLE PHARMACEUTICALS BUD 2025 PH INJECTABLE PHARMACEUTICALS LIE 2024 PH INJECTABLE PHARMACEUTICALS LIE 2025 OF PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL TO CONSUMBLES 2016 - STAPLES MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO HARMACEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICALS INCHEMBANIA INC. PALADIN PHARMA INC. FRESENIUS KABI CANADA LTD. LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS	October 1, 2024 October 1, 2025 October 1, 2015 October 1, 2016 October 1, 2016 October 1, 2015 October 1, 2016 October 1, 2017 May 1, 2016 January 1, 2017 February 1, 2017	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2027 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
HH	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13691 C13803 C13804 C13805 C13911 C14027 C14127 C14127 C14202 C8669 C8672 C8673 C8914 C8915 C8915 C8915 C8915 C8915 C8916 C99109 C9111	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS BBC 2024 PH INJECTABLE PHARMACEUTICALS BWC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS SED 2024 PH INJECTABLE PHARMACEUTICALS NOW 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS HE 2024 PH INJECTABLE PHARMACEUTICALS BUD 2025 PH INJECTABLE PHARMACEUTICALS BUD 2025 PH INJECTABLE PHARMACEUTICALS LIE 2024 PH INJECTABLE PHARMACEUTICALS LIE 2025 OF PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 MMNCL TO CONSUMBLES 2016 - STAPLES MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO HARMACEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICALS KNIGHT THERAPEUTICALS INCHEMBANIA INC. PALADIN PHARMA INC. FRESENIUS KABI CANADA LTD. LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS	October 1, 2024 October 1, 2025 October 1, 2015 October 1, 2016 October 1, 2016 October 1, 2015 October 1, 2016 October 1, 2017 May 1, 2016 January 1, 2017 February 1, 2017	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2027 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13645 C13689 C13689 C13689 C136801 C13603 C13691 C13603 C13691 C13603 C13691 C14057 C14127 C14127 C14127 C14202 C6669 C6673 C8914 C69964 C9905 C9967	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SRC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS HIN 2024 PH INJECTABLE PHARMACEUTICALS HEN 2024 PH INJECTABLE PHARMACEUTICALS HEN 2024 PH INJECTABLE PHARMACEUTICALS LED 2025 PH INJECTABLE PHARMACEUTICALS BUS 2024 PH INJECTABLE PHARMACEUTICALS INCONEG FRIX 2024 PH INJECTABLE PHARMACEUTICALS INCONEG FRIX 2024 PH INJECTABLE PHARMACEUTICALS BUS 2025 PH INJECTABLE PHARMACEUTICALS BUS 2025 PH INJECTABLE PHARMACEUTICALS SUPPORT SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - FED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 - MMNCL DECONTAMINATION PRODUCTS 2017 - SETINGE CANADALTD	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. PALADIN PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEE LEO PHARMA INC LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS ECOLAB GETINGE CANADA LTD	October 1, 2024 October 1, 2015 October 1, 2015 October 1, 2015 October 1, 2016 May 1, 2016 May 1, 2016 January 1, 2017 February 1, 2017 February 1, 2017	September 30, 2025 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
H H H H H H H H H H H H H H H H H H H	C13341 C13463 C13464 C13542 C13645 C13689 C13661 C13803 C13805 C13801 C13805 C13911 C14057 C14127 C14127 C14202 C6869 C8673 C8914 C8915 C8917 C8916 C8917 C8917 C8917 C8917 C9917 C9111	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS NED 2024 PH INJECTABLE PHARMACEUTICALS SED 2024 PH INJECTABLE PHARMACEUTICALS HIN 2025 ON PELVIC SUPPORT PRODUCTS 2015 - SOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - JUMP OR SPONGES 2016 - AMD OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 - MMNCL DECONTAMINATION PRODUCTS 2017 - STERIS MMNCL DECONTAMINATION PRODUCTS 2017 - SOUTHMEDIC MMNCL DECONTAMINATION PRODUCTS 2017 - SOUTHMEDIC	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. PALADIN PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEL LEO PHARMA INC HERSENIUS KABI CANADA LTD LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J BUSTON SCIENTIFIC J&J BUSTON SCIENTIFIC J&J BUSTON SCIENTIFIC STAPLES PROFESSIONAL CAN STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS CANADA LTD GETINGE CANADA LTD GETINGE CANADA LTD GETINGE CANADA LTD	October 1, 2024 October 1, 2015 October 1, 2016 January 1, 2017 January 1, 2017 May 1, 2016 June 20, 2016 January 1, 2017 February 1, 2017 February 1, 2017 February 1, 2017	September 30, 2025 May 31, 2028 May 31, 2027 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025 March 31, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND
HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH	C13341 C13463 C13464 C13542 C13615 C13689 C13690 C13690 C13691 C13803 C13804 C13805 C13911 C14027 C14202 C8669 C8672 C8673 C8914 C8915 C8955 C8914 C8915 C8911 C99113 C9113	PH SERVICE CERTIFICATION OF CONTROLLED AREAS + CONTAINMENT PRIMARY ENGINEERING CONTROLS FOR COMPOUNDING STERILE PREPARATIONS STS 2024 PH ONCOLOGY SS PFI 2024 PH INJECTABLE PHARMACEUTICALS ORG 2024 PH INJECTABLE PHARMACEUTICALS SFR 2024 PH INJECTABLE PHARMACEUTICALS SRC 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS SUM 2024 PH INJECTABLE PHARMACEUTICALS NO 2024 PH INJECTABLE PHARMACEUTICALS HIN 2024 PH INJECTABLE PHARMACEUTICALS HEN 2024 PH INJECTABLE PHARMACEUTICALS HEN 2024 PH INJECTABLE PHARMACEUTICALS LED 2025 PH INJECTABLE PHARMACEUTICALS BUS 2024 PH INJECTABLE PHARMACEUTICALS INCONEG FRIX 2024 PH INJECTABLE PHARMACEUTICALS INCONEG FRIX 2024 PH INJECTABLE PHARMACEUTICALS BUS 2025 PH INJECTABLE PHARMACEUTICALS BUS 2025 PH INJECTABLE PHARMACEUTICALS SUPPORT SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - BOSTON SCIENTIFIC OR PELVIC SUPPORT PRODUCTS 2015 - FED LEAF OR SPONGES 2016 - AMD OR SPONGES 2016 - DERMA MMNCL STERILIZATION AND ENDOSCOPIC REPROCESSING PRODUCTS 2016 - MMNCL DECONTAMINATION PRODUCTS 2017 - SETINGE CANADALTD	SUPERIOR TESTING SERVICES PFIZER CANADA ULC ORGANON CANADA INC. SEAFORD PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMACEUTICALS B. BRAUN OF CANADA LTD SUMITOMO PHARMA CANADA I ALCON CANADA INC. NOVO NORDISK CANADA INC. NOVO NORDISK CANADA INC. PALADIN PHARMACEUTICALS KNIGHT THERAPEUTICS INC. PALADIN PHARMA INC. HOFFMANN-LA ROCHE LIMITEE LEO PHARMA INC LEO PHARMA INC LEADIANT BIOSCIENCES, INC. BOSTON SCIENTIFIC J&J RED LEAF MEDICAL AMD DERMA SCIENCES ADVANCED STERILIZATION PR STERIS CANADA SALES ULC STAPLES PROFESSIONAL CAN STERIS ECOLAB GETINGE CANADA LTD	October 1, 2024 October 1, 2015 October 1, 2015 October 1, 2015 October 1, 2016 May 1, 2016 May 1, 2016 January 1, 2017 February 1, 2017 February 1, 2017	September 30, 2025 May 31, 2028 May 31, 2024	May 31, 2025 May 31, 2025 November 30, 2024 November 30, 2024 June 30, 2025 June 30, 2025 June 30, 2025 March 31, 2025 March 31, 2025	Appendix A - Limited Tender	B(ii) A(i) A(i) A(i) A(i) A(i) A(i) A(i)	P-ND P-ND P-ND P-ND P-ND P-ND P-ND P-ND

	eport Definintions and Reference Tables
	Reported Spend indicates Membra provided data for the Atlessation Penod. Note that contracts may have started or ended at various points within the Atlessation penod. Data compiled from October 2023 to Septembe
	- ND indicates Member participation on contract, however spend data not provided/available. P - Not Participating
٠,	
-	Appendix A – Limited Tendering (Article 513)
ŀ	mited Tendering: means a procurement method whereby the procuring entity contacts a supplier or supplier or suppliers of its choice. In accordance with the CFTA Chapter 5 (Government Procurement), an organization may use Limited Tendering in e following circumstances, provided that it does not use this provision for the purpose of avoiding competition among suppliers or in a manner that discriminates against suppliers or any other Party or protects its own suppliers.
	□(a) if
i)	(i) no tenders were submitted or no suppliers requested participation;
ii)	□ (i) no tenders that conform to the essential requirements of the tender documentation were submitted;
iii)	□ (ii) no suppliers satisfied the conditions for participation; or
iv)	(v) the submitted tenders were collusive provided that the requirements of the tender documentation are not substantially modified;
	(b) if the goods or services can be supplied only by a particular supplier and no reasonable alternative or substitute goods or services exist for any of the following reasons:
i)	(i) the requirement is for a work of art,
ii)	(ii) the prefection of patents, capyrights, or other exclusive rights;
iii)	(ii) due te an absence of competitien fer technical reasens;
iv)	(iv) the supply of goods or services is controlled by a supplier that is a statutory monopoly; (iv) to ensure compatibility with existing goods, or to maintain specialized goods that must be maintained by the manufacturer of those goods or its representative;
v) vi)	□ (v) to ensure compationity with existing geods, or to maintain specialized geods that must be maintained by the manufacture of the insurgation of its representative; □ (v) week is to be performed on properly by a centractor according the provisions of a warranty or guarantee held in respect of the property or the original work;
vii)	(iv) which is to be performed an a leased building or related properly a gratians thereof, that may be performed only by the lesser; or
viii	(viii) the procurement is for subscriptions to newspapers, magazines, of other periodicals;
	(c) for additional deliveries by the original supplier of goods or services that were not included in the initial procurement, if a change of supplier for such additional goods or services:
)	(i) cannot be made for economic or technical reasons such as requirements of interchangeability or interoperability with existing equipment, software, services, or installations procured under the initial procurement; and
i)	(i) would cause significant inconvenience or substantial duplication of costs for the procuring entity;
1	(ii) is inconversesary, and not reasons or ugency brought about by events unionesceaple by the procuring entity, the global or services could not be obtained in time using open tendering.
1	(i) a procuring entity procures a prototype of a first good or service that is developed in the course of, and for, a particular contract for research, experiment, study, or original development. Original development of a first good or service
	may include limited production or supply in order to incorporate the results of field testing and to demonstrate that the good or service is suitable for production or supply in quantity to acceptable quality standards, but does not include
-	quantity production or supply to establish commercial viability or to recover research and development costs; (g) for purchases made under exceptionally advantageous conditions that only arise in the very short term in the case of unusual disposals such as those arising from liquidation, receivership, or bankrupt cy, but not for foutine purchases
	from regular suppliers;
	(h) if a contract is awarded to a winner of a design contest previded that:
i)	(i) the contest has been organized in a manner that is consistent with the principles of this Chapter, in particular relating to the publication of a tender notice; and (ii) the participants are judged by an independent jury with a view to a design contract being awarded to a winner; or
,	□ (i) if geeds or consulting services regarding matters of a centification or privileged nature are to be purchased and the disclosure of these matters through an open tendering process could reasonably be expected to compromise
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest.
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest.
	gevernment confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B - Non-Application (Article 504)
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest.
1	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to:
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives,
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the
	gevernment confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract waverded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter;
	government confidentiality, result in the waiver of privilege, cause economic disruption, or otherwise be contrary to the public interest. Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the
	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the presement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the me conditions prevail or are a disguised restriction on trade;
	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the nights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the americanditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of:
 	Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the time conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) fiscal agency or depository services,
i) ii)	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the presement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the me conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) injudication and management services for regulated financial institutions; or
i) ii)	Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the time conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) fiscal agency or depository services,
i) ii) iii)	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the precurement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of. (ii) fiscal agency or depository services; (iii) liquidation and management services for regulated financial institutions; or (iii) isquidation and management services for regulated financial institutions; or
iii) iii)	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the presement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the nights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) fiscal agency or depository services; (g) if is services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (h) procurement of: (if) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution;
i) ii) iii) iii)	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) figuriation and management services for regulated financial institutions; or (ii) Biquidation and management services for regulated financial institutions; or (iii) procurement of: (b) procurement of: (c) procurement of: (d) procurement of: (e) procurement of: (iv) procurement of:
i) ii) iii) iii)	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the presement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the sme conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition or. (g) inscall agency or depository services for regulated financial institutions, or (h) procurement or acquisition on an an application of public debt, including loans and government bonds, notes, and other securities; (h) procurement of: (i) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (ii) health services or social services.
i) ii) iii) iii)	Appendix B – Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the nights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disquised restriction on trade; (g) procurement or acquisition of: (g) procurement or acquisition of: (ii) fiscal agency or depository services; (iii) fiquidation and management services for regulated financial institutions; or (iii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (iv) procurement of: (iv) financial institution; (iv) financial institution; (iv) health services or social services, (iv) health services or social services, (iv) services of expert witnesses or factual witnesses used in court or legal proceedings; or
	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the presement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the sme conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition or, (g) inscall agency or depository services for regulated financial institutions, or (h) procurement or acquisition on an an appearant services for regulated financial institutions, or (h) procurement or. (h) procurement or. (h) procurement or. (h) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (ii) health services or social services.
	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (g) figuriation and management services for regulated financial institutions; or (ii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities; (iii) inancial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (iii) health services or social services (iv) services of expect witnesses or factual witnesses used in court or legal proceedings; or (iv) services of expect witnesses or factual witnesses used in court or legal proceedings; or (iv) procurement of goods or services.
	Appendix B – Non-Application (Article 504) Appendix B – Non-Application (Article 504) Appendix B – Non-Application (Article 504) (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the greement includes rules for awarding contracts that differ from the obligations of this Chapter, (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the me conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of: (ii) fiscal agency or depository services, (iii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (iv) procurement of: (iv) procurement of: (iv) procurement of: (iv) services or social services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (iv) services that may, under applicable law, only be provided by licensed lawyers or notaries, or (iv) services that may, under applicable law, only be provided by licensed lawyers or notaries, or (iv) services that may, under applicable law, only be provided by licensed lawyers or notaries, or (iv) procurement of goods or services.
} ii)	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the preement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or renatol diand, existing buildings, or other immovable property, or the nights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the measures of agency or depository services; (ii) liquidation and management services for regulated financial institutions; or (iii) liquidation and management services for regulated financial institutions; or (iii) procurement of. (iii) procurement of. (iii) health services or social services, (iii) health services or social services, (iii) envices of expert witherses or factual witnesses used in court or legal proceedings; or (iv) recruites of vervices of expert witnesses or factual witnesses used in court or legal proceedings; or (iv) procurement of government of powernment of powernment of powernment of powernment or power or factual witnesses used in court or legal proceedings; or (iv) procurement of government or factual witnesses used in court or legal proceedings; or (iv) procurement or goods or services: (iv) procurement or powernment bodd or activity on behalf of an entity not covered by this Chapter; (iv) by a procuring entity on behalf of an entity not covered by this Chapter; (iv) by non-governmental boddes that exercise governmental authority delegated to them;
i) ii) iii) iii) iii) iii) iii)	Appendix B – Non-Application (Article 504) (b) public employment contracts; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part. by the organization, only to the extent that the greenent includes ruses for awarding contracts that differ from the obligations of this Chapter, (b) acquisition or rental of land, existing buildings, or other minovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the mace conditions prevaid or are a disguised restriction on trade; (g) procurement or acquisition of: (g) is existed to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (h) procurement of: (g) is an applicable or the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (h) the salth services respecting the management of government f nancial ansitution, (g) is an acquisition or a management services of services, (g) is envices respecting the management of government f nancial ansitution, (g) is envices respecting the management services, or social serv
i) ii) ii) ii) ii) ii) ii) ii) ii) ii)	Appendix B – Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the prement includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not applied in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the ame conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition of (g) fiscal agency or depository services; (g) ill juiculation and management services for regulated financial institutions; or (g) ill juiculation and management services for regulated financial institutions; or (g) infancial services respecting the management of government f nancial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; institution; (g) in health services or social services; (g) in services of expert withesses or factual withesses used in court or legal proceedings; or (g) procurement of government of government of provided by incensed lawyers or notaries; or (g) procurement of government of provided by the provided by incensed lawyers or notaries; or (g) procurement of goods or services: (g) in procurement of goods or services: (g) in procurement of goods or services: (g) procurement of goods or services: (g) procurement of goods or services: (g) procurement of goods or servic
i) ii) iii) iiii) iii)	Appendix B – Non-Application (Article 504) (b) public employment contracts; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part. by the organization, only to the extent that the greenent includes ruses for awarding contracts that differ from the obligations of this Chapter, (b) acquisition or rental of land, existing buildings, or other minovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the mace conditions prevaid or are a disguised restriction on trade; (g) procurement or acquisition of: (g) is existed to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (h) procurement of: (g) is an applicable or the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (h) the salth services respecting the management of government f nancial ansitution, (g) is an acquisition or a management services of services, (g) is envices respecting the management of government f nancial ansitution, (g) is envices respecting the management services, or social serv
i) iii) iii) iii) iii) iii) iii) iii)	Appendix B - Non-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the precent includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the me conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition or or acquisition or or depository services; (g) is call agency or depository services, or generated to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities; (liv) procurement of: (g) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (g) financial services or social services; (g) procurement of goods or services: (g) procurement of goods or services or factual witnesses used in court or legal proceedings; or (g) procurement of goods or services: (g) year or the proceedings or including entity on behalf of an entity not covered by this Chapter; (g) year or primarily from donations that require the procurement to be conducted in a manner inconsistent with this Chapter;
} i) ii) } } ; j) iii)	Appendix B - Non-Application (Article 504) Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts, (b) non-legally binding agreements, (c) any form of assistance, such as grants, loans, equity influsions, guarantees, and fiscal incentives, (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the precent includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon; (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the eme conditions preval or are a disguised restriction on trade; (g) procurement or acquisition or: [0] fiscal agency or depository services, [1] (ii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities, (iii) procurement of: [1] (iii) hearth services or social services respecting the management of government financial assets and liabitities (ii.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; [1] (iii) hearth services or social services used in court or legal proceedings; or [1] (iii) procurement of goods or services [2] (iii) services financy, under applicable law, only be provided by licensed lawyers or notaries, or [3] (iii) procurement of goods or services [3] (iii) procurement of goods or services [4] (iv) procurement of goods or services [5] (iv) procurement of goods or services [6] (iv) procurement of goods or services or secret with services or secret with services or secret with services or secret with services or secr
i)	Appendix B - Non-Application (Article 504) on-Application: means the CFTA Chapter 5 (Government Procurement) does not apply to: (a) public employment contracts; (b) non-legally binding agreements; (c) any form of assistance, such as grants, loans, equity infusions, guarantees, and fiscal incentives; (d) a contract awarded under a cooperation agreement between a Party and an international cooperation organization if the procurement is financed, in whole or in part, by the organization, only to the extent that the precent includes rules for awarding contracts that differ from the obligations of this Chapter; (e) acquisition or rental of land, existing buildings, or other immovable property, or the rights thereon, (f) measures necessary to protect intellectual property, provided that the measures are not appled in a manner that would constitute a means of arbitrary or unjustifiable discrimination between Parties where the me conditions prevail or are a disguised restriction on trade; (g) procurement or acquisition or or depository services; (ii) services related to the sale, redemption, and distribution of public debt, including loans and government bonds, notes, and other securities; (iv) procurement of: (iii) financial services respecting the management of government financial assets and liabilities (i.e. treasury operations), including ancillary advisory and information services, whether or not delivered by a financial institution; (iii) health services or social services; (iv) services of appet witnesses or factual witnesses used in court or legal proceedings; or (iv) services that may, under applicabile law, only be provided by licensed lawyers or notaries; or (iv) services of goods or services. (iii) by a procuring entity on behalf of an entity not covered by this Chapter; (iv) by a procuring entity on behalf of an entity not covered by this Chapter; (iv) by non-governmental bodies that exercise governmental authority delegated to them; (iv) under a commercial agreement between a procuring entity which ope

APPENDIX A - HOSPITAL REPORT ON CONSULTANT USE

Name of Hospital: Dryden Regional Health Centre

OH Region: North

Reporting Period: April 1, 2024 to March 31, 2025

No.	Consultant Firm Name(s)	Name and Title of Consulting Contract	Contract Term If the contract term has been extended, please include the original contract term and the amended contract term	Procurement Value (A) Original value plus (B) Value of amendments and (C) Total procurement value (\$) / Total Paid	Consultant Selection Process (Open Competitive, Invitational Competitive, Non-competitive) If non-competitive, please provide an explanation	Modifications to Agreement (Yes/No) If Yes, did the procurement documents permit modifications to the term or value of the agreement?
1.	MNP LLP	Audit Service	April 1, 2024 to March 31, 2025	Total Paid for the Reporting Period = \$38,110	Invitational Competitive	No
2.	Mondelis Actuarial Services	Post-Employment Benefits	April 1, 2024 to March 31, 2025	Total Paid for the Reporting Period = \$1,525	Open Competitive	No
3.	Blackstone	Natural Gas and Electricity Procurement Advisor Services and Reporting	December 2024 to October 2026	Total Paid for the Reporting Period = \$109,251	Open Competitive	No
4.	807 Management	Financial Services	December 1, 2023 to June 30, 2024 Amended to July 31, 2024	Period = \$49,720	Non-Competitive; CFO vacancy resulted in need for interim CFO services.	No
5.	NRG Management	Chiller Replacement Project	To project completion	Total Paid for the Reporting Period = \$322,752	Open Competitive	No
6.	Colliers Project Leaders Inc.	Pharmacy Project Management	To project completion	Total Paid for the Reporting Period = \$161,260	Open Competitive	No

Preservation of Solicitor -client privilege:

This legislation maintains the integrity of solicitor client privilege, litigation privilege and settlement privilege, and does not require the disclosure of information subject to any of these privileges.

While hospitals are expected to report on their retention of lawyers and law firms for the provision of consulting services, they are not required to report on instances where they have retained lawyers and law firms to provide legal advice, draft legal documents, conduct litigation on behalf of a hospital, or otherwise for the purpose of providing legal services to a hospital.